The research work entitled “Design, Development and Preclinical Evaluation of Soberana 02, a Cuban vaccine against COVID-19” was granted the Jorge Gavilondo Cowley in Memóriam Annual Immunology Award, during the recent Latin American and Caribbean Congress of Immunology (Alaci-2022), reported the Finlay Vaccine Institute on its official Twitter account.
 
Soberana 02 is a conjugated anti-Covid-19 vaccine, developed by the Finlay Institute, which, after preclinical research, was tested in phase I, II and III clinical trials, demonstrating its safety, immunogenicity and effectiveness in preventing symptomatic infections at a rate of 71%, with only two doses, and 92.4%, in combination with a third dose of Soberana Plus.
 
Moreover, this was the immunogen with which the world’s first pediatric vaccination campaign against COVID-19 was conducted, administered to Cuban children between two and 18 years of age, with positive results.
 
The Alaci-2022 conference, in its 13th edition, took place June 6-10, at the Meliá Internacional Hotel in Varadero, and was attended by representatives from prestigious scientific institutions, including the Finlay Institute, the Center for Genetic Engineering and Biotechnology, and the Molecular Immunology Center, who presented their most outstanding findings and products to Cuban and international participants.